Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

Janssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...

Despite this, real-world data comparing guselkumab and risankizumab effectiveness and safety are quite limited. In the literature, Ruggiero et al. and Viopulus et al. compared the efficacy and safety ...

The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tremfya (guselkumab) (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC).

As with all products, we will keep its safety under close review The Medicines and Healthcare products Regulatory Agency ...

As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with ...

PARIS, May 7, 2025 /PRNewswire/ -- This is a report from China.org.cn: At the 2025 Foire de Paris held from April 30 to May 11, more than 200 items of Hehe Culture from Taizhou, Zhejiang province, ...

Frail Medicare Patients Face Primary Care Follow-Up Gaps Medicare beneficiaries, especially patients with frailty and those discharged to skilled nursing facilities after hospitalization, face ...